Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1132

1.

The close relationship between heparanase and epithelial mesenchymal transition in gastric signet-ring cell adenocarcinoma.

Shah S, Fourgeaud C, Derieux S, Mirshahi S, Contant G, Pimpie C, Lo Dico R, Soria J, Pocard M, Mirshahi M.

Oncotarget. 2018 Sep 18;9(73):33778-33787. doi: 10.18632/oncotarget.26042. eCollection 2018 Sep 18.

PMID:
30333909
2.

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

Watson S, Menis J, Baldini C, Martin-Romano P, Michot JM, Hollebecque A, Armand JP, Massard C, Soria JC, Postel-Vinay S, Paoletti X.

Br J Cancer. 2018 Oct 17. doi: 10.1038/s41416-018-0245-0. [Epub ahead of print]

PMID:
30327567
3.

LONG-TERM SURVIVAL IN PATIENTS RESPONDING TO ANTI-PD-1/PD-L1 THERAPY AND DISEASE OUTCOME UPON TREATMENT DISCONTINUATION.

Gauci ML, Lanoy E, Champiat S, Caramella C, Ammari S, Aspeslagh S, Varga A, Baldini C, Bahleda R, Gazzah A, Michot JM, Postel-Vinay S, Angevin E, Ribrag V, Hollebecque A, Soria JC, Robert C, Massard C, Marabelle A.

Clin Cancer Res. 2018 Oct 8. pii: clincanres.0793.2018. doi: 10.1158/1078-0432.CCR-18-0793. [Epub ahead of print]

PMID:
30297458
4.

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E.

Eur J Cancer. 2018 Sep 29;104:1-8. doi: 10.1016/j.ejca.2018.07.011. [Epub ahead of print]

PMID:
30278378
5.

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.

Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz PE, Revel MP, Westeel V, Dixmier A, Tredaniel J, Dehette S, Decroisette C, Prevost A, Pichon E, Fabre E, Soria JC, Friard S, Stern JB, Jabot L, Dennewald G, Pavy G, Petitpretz P, Tourani JM, Alifano M, Chatellier G, Girard P.

Eur Respir J. 2018 Oct 4;52(4). pii: 1801220. doi: 10.1183/13993003.01220-2018. Print 2018 Oct.

PMID:
30262574
6.

Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?

Prud'homme C, Deschamps F, Allorant A, Massard C, Hollebecque A, Yevich S, Ngo-Camus M, Gravel G, Nicotra C, Michiels S, Scoazec JY, Lacroix L, Solary E, Soria JC, De Baere T, Tselikas L.

Eur J Cancer. 2018 Nov;103:108-119. doi: 10.1016/j.ejca.2018.08.003. Epub 2018 Sep 14.

PMID:
30223224
7.

Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.

Mir O, Azaro A, Merchan J, Chugh R, Trent J, Rodon J, Ohnmacht U, Diener JT, Smith C, Yuen E, Oakley GJ 3rd, Le Cesne A, Soria JC, Benhadji KA, Massard C.

Eur J Cancer. 2018 Nov;103:88-97. doi: 10.1016/j.ejca.2018.08.012. Epub 2018 Sep 12.

PMID:
30218977
8.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Sep 6. doi: 10.1001/jamaoncol.2018.3676. [Epub ahead of print]

PMID:
30193240
9.

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C.

Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14.

PMID:
30120041
10.

Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors.

Koeppel F, Bobard A, Lefebvre C, Pedrero M, Deloger M, Boursin Y, Richon C, Chen-Min-Tao R, Robert G, Meurice G, Rouleau E, Michiels S, Massard C, Scoazec JY, Solary E, Soria JC, André F, Lacroix L.

Cancer J. 2018 Jul/Aug;24(4):153-162. doi: 10.1097/PPO.0000000000000322.

PMID:
30119077
11.

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.

Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin A, Ding K, Le Teuff G, Shepherd FA, Pignon JP, Graziano SL, Kratzke R, Soria JC, Seymour L, Govindan R, Michiels S.

J Clin Oncol. 2018 Aug 14:JCO2018781963. doi: 10.1200/JCO.2018.78.1963. [Epub ahead of print]

PMID:
30106638
12.

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.

Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC.

Eur J Cancer. 2018 Sep;101:201-209. doi: 10.1016/j.ejca.2018.06.031. Epub 2018 Aug 1.

PMID:
30077125
13.

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.

Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2018 Sep;101:160-164. doi: 10.1016/j.ejca.2018.06.005. Epub 2018 Jul 30.

PMID:
30071444
14.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J.

Ann Oncol. 2018 Jul 28. doi: 10.1093/annonc/mdy261. [Epub ahead of print] No abstract available.

PMID:
30060089
15.

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.

Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR, Yuen ESM, Benhadji KA, Rodon J.

Ann Oncol. 2018 Sep 1;29(9):1911-1917. doi: 10.1093/annonc/mdy244.

PMID:
30060061
16.

Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer.

Rotolo F, Zhu CQ, Brambilla E, Graziano SL, Olaussen K, Le-Chevalier T, Pignon JP, Kratzke R, Soria JC, Shepherd FA, Seymour L, Michiels S, Tsao MS.

Transl Lung Cancer Res. 2018 Jun;7(3):416-427. doi: 10.21037/tlcr.2018.05.01.

17.

Short closure time values in PFA-100® are related to venous thrombotic risk. Results from the RETROVE Study.

Vázquez-Santiago M, Vilalta N, Cuevas B, Murillo J, Llobet D, Macho R, Pujol-Moix N, Carrasco M, Mateo J, Fontcuberta J, Soria JM, Souto JC.

Thromb Res. 2018 Sep;169:57-63. doi: 10.1016/j.thromres.2018.07.012. Epub 2018 Jul 11.

PMID:
30015229
18.

Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.

Soria JC, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, Blackhall F, Mok TS, Wu YL, Pestova K, Wilner KD, Polli A, Paolini J, Lanzalone S, Green S, Camidge DR.

Ann Oncol. 2018 Sep 1;29(9):1964-1971. doi: 10.1093/annonc/mdy242.

PMID:
30010763
19.

The legacy of Thomas Tursz: building a leading comprehensive cancer center in Europe.

Soria JC, Baselga J, Piccart M.

Ann Oncol. 2018 Sep 1;29(9):1887-1888. doi: 10.1093/annonc/mdy252. No abstract available.

PMID:
30010759
20.

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.

Ricordel C, Friboulet L, Facchinetti F, Soria JC.

Ann Oncol. 2018 Jul 3. doi: 10.1093/annonc/mdy222. [Epub ahead of print] No abstract available.

PMID:
29982319
21.

Evaluation of the GeneXpert MTB/RIF in patients with presumptive tuberculous meningitis.

Metcalf T, Soria J, Montano SM, Ticona E, Evans CA, Huaroto L, Kasper M, Ramos ES, Mori N, Jittamala P, Chotivanich K, Chavez IF, Singhasivanon P, Pukrittayakamee S, Zunt JR.

PLoS One. 2018 Jun 18;13(6):e0198695. doi: 10.1371/journal.pone.0198695. eCollection 2018.

22.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC.

JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775.

23.

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.

Besle S, Schultz E, Hollebecque A, Varga A, Baldini C, Martin P, Postel-Vinay S, Bahleda R, Gazzah A, Michot JM, Marabelle A, Angevin E, Armand JP, Ribrag V, Soria JC, Massard C.

Eur J Cancer. 2018 Jul;98:17-22. doi: 10.1016/j.ejca.2018.04.019. Epub 2018 May 30.

PMID:
29859337
24.

Correlates of viral suppression among HIV-infected men who have sex with men and transgender women in Lima, Peru.

Rich KM, Valencia Huamaní J, Kiani SN, Cabello R, Elish P, Florez Arce J, Pizzicato LN, Soria J, Wickersham JA, Sanchez J, Altice FL.

AIDS Care. 2018 Nov;30(11):1341-1350. doi: 10.1080/09540121.2018.1476657. Epub 2018 May 30.

PMID:
29843518
25.

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.

Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC.

Ann Oncol. 2018 Feb 23. doi: 10.1093/annonc/mdy076. [Epub ahead of print]

PMID:
29788155
26.

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C.

J Clin Oncol. 2018 May 7:JCO2018782292. doi: 10.1200/JCO.2018.78.2292. [Epub ahead of print]

PMID:
29733771
27.

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica.

Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, Jamme P, Gelli M, Goere D, Lacroix L, Adam J, Heukamp L, Trenta P, Hembrough T, Soria JC, Sternberg C, Ducreux M.

Tumori. 2018 Mar 1:300891618763215. doi: 10.1177/0300891618763215. [Epub ahead of print]

PMID:
29714649
28.

A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.

Claret L, Jin JY, Ferté C, Winter H, Girish S, Stroh M, He P, Ballinger M, Sandler A, Joshi A, Rittmeyer A, Gandara D, Soria JC, Bruno R.

Clin Cancer Res. 2018 Jul 15;24(14):3292-3298. doi: 10.1158/1078-0432.CCR-17-3662. Epub 2018 Apr 23.

PMID:
29685883
29.

Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation.

Bull ME, Mitchell C, Soria J, Styrchak S, Williams-Wietzikoski C, Legard J, McKernan-Mullin J, Kraft K, Onchiri F, Stern J, Holte S, Ryan KJ, Acosta EP, La Rosa A, Coombs RW, Ticona E, Frenkel LM.

AIDS. 2018 Jul 17;32(11):1389-1401. doi: 10.1097/QAD.0000000000001824.

30.

Temperature Effects Explain Continental Scale Distribution of Cyanobacterial Toxins.

Mantzouki E, Lürling M, Fastner J, de Senerpont Domis L, Wilk-Woźniak E, Koreivienė J, Seelen L, Teurlincx S, Verstijnen Y, Krztoń W, Walusiak E, Karosienė J, Kasperovičienė J, Savadova K, Vitonytė I, Cillero-Castro C, Budzyńska A, Goldyn R, Kozak A, Rosińska J, Szeląg-Wasielewska E, Domek P, Jakubowska-Krepska N, Kwasizur K, Messyasz B, Pełechaty A, Pełechaty M, Kokocinski M, García-Murcia A, Real M, Romans E, Noguero-Ribes J, Duque DP, Fernández-Morán E, Karakaya N, Häggqvist K, Demir N, Beklioğlu M, Filiz N, Levi EE, Iskin U, Bezirci G, Tavşanoğlu ÜN, Özhan K, Gkelis S, Panou M, Fakioglu Ö, Avagianos C, Kaloudis T, Çelik K, Yilmaz M, Marcé R, Catalán N, Bravo AG, Buck M, Colom-Montero W, Mustonen K, Pierson D, Yang Y, Raposeiro PM, Gonçalves V, Antoniou MG, Tsiarta N, McCarthy V, Perello VC, Feldmann T, Laas A, Panksep K, Tuvikene L, Gagala I, Mankiewicz-Boczek J, Yağcı MA, Çınar Ş, Çapkın K, Yağcı A, Cesur M, Bilgin F, Bulut C, Uysal R, Obertegger U, Boscaini A, Flaim G, Salmaso N, Cerasino L, Richardson J, Visser PM, Verspagen JMH, Karan T, Soylu EN, Maraşlıoğlu F, Napiórkowska-Krzebietke A, Ochocka A, Pasztaleniec A, Antão-Geraldes AM, Vasconcelos V, Morais J, Vale M, Köker L, Akçaalan R, Albay M, Špoljarić Maronić D, Stević F, Žuna Pfeiffer T, Fonvielle J, Straile D, Rothhaupt KO, Hansson LA, Urrutia-Cordero P, Bláha L, Geriš R, Fránková M, Koçer MAT, Alp MT, Remec-Rekar S, Elersek T, Triantis T, Zervou SK, Hiskia A, Haande S, Skjelbred B, Madrecka B, Nemova H, Drastichova I, Chomova L, Edwards C, Sevindik TO, Tunca H, Önem B, Aleksovski B, Krstić S, Vucelić IB, Nawrocka L, Salmi P, Machado-Vieira D, de Oliveira AG, Delgado-Martín J, García D, Cereijo JL, Gomà J, Trapote MC, Vegas-Vilarrúbia T, Obrador B, Grabowska M, Karpowicz M, Chmura D, Úbeda B, Gálvez JÁ, Özen A, Christoffersen KS, Warming TP, Kobos J, Mazur-Marzec H, Pérez-Martínez C, Ramos-Rodríguez E, Arvola L, Alcaraz-Párraga P, Toporowska M, Pawlik-Skowronska B, Niedźwiecki M, Pęczuła W, Leira M, Hernández A, Moreno-Ostos E, Blanco JM, Rodríguez V, Montes-Pérez JJ, Palomino RL, Rodríguez-Pérez E, Carballeira R, Camacho A, Picazo A, Rochera C, Santamans AC, Ferriol C, Romo S, Soria JM, Dunalska J, Sieńska J, Szymański D, Kruk M, Kostrzewska-Szlakowska I, Jasser I, Žutinić P, Gligora Udovič M, Plenković-Moraj A, Frąk M, Bańkowska-Sobczak A, Wasilewicz M, Özkan K, Maliaka V, Kangro K, Grossart HP, Paerl HW, Carey CC, Ibelings BW.

Toxins (Basel). 2018 Apr 13;10(4). pii: E156. doi: 10.3390/toxins10040156.

31.

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V.

Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9.

PMID:
29650362
32.

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

Herin H, Aspeslagh S, Castanon E, Dyevre V, Marabelle A, Varga A, Postel Vinay S, Michot JM, Ribrag V, Gazzah A, Bahleda R, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C.

Eur J Cancer. 2018 May;95:68-74. doi: 10.1016/j.ejca.2018.03.002. Epub 2018 Apr 7.

PMID:
29635146
33.

Osimertinib in EGFR Mutation-Positive Advanced NSCLC.

Soria JC, Ramalingam SS.

N Engl J Med. 2018 Mar 29;378(13):1262-1263. doi: 10.1056/NEJMc1801669. No abstract available.

34.

Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer.

Muñoz Martín AJ, Ortega I, Font C, Pachón V, Castellón V, Martínez-Marín V, Salgado M, Martínez E, Calzas J, Rupérez A, Souto JC, Martín M, Salas E, Soria JM.

Br J Cancer. 2018 Apr;118(8):1056-1061. doi: 10.1038/s41416-018-0027-8. Epub 2018 Mar 28.

35.

Immuno-Oncology in Cancer Care is a Fantastic Opportunity for Interventional Oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative.

de Baère T, Tselikas L, Deschamps F, Soria JC, Marabelle A.

Cardiovasc Intervent Radiol. 2018 Jun;41(6):825-827. doi: 10.1007/s00270-018-1935-y. No abstract available.

PMID:
29549416
36.

Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers?

Mirghani H, Lacroix L, Rossoni C, Sun R, Aupérin A, Casiraghi O, Villepelet A, Lacave R, Faucher G, Marty V, Ferté C, Soria JC, Even C.

Eur J Cancer. 2018 May;94:61-69. doi: 10.1016/j.ejca.2018.02.013. Epub 2018 Mar 20.

PMID:
29533868
37.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

38.

lme4qtl: linear mixed models with flexible covariance structure for genetic studies of related individuals.

Ziyatdinov A, Vázquez-Santiago M, Brunel H, Martinez-Perez A, Aschard H, Soria JM.

BMC Bioinformatics. 2018 Feb 27;19(1):68. doi: 10.1186/s12859-018-2057-x.

39.

A novel antibody-based approach to detect the functional ERCC1-202 isoform.

Kuo MS, Adam J, Dorvault N, Robin A, Friboulet L, Soria JC, Olaussen KA.

DNA Repair (Amst). 2018 Apr;64:34-44. doi: 10.1016/j.dnarep.2018.02.002. Epub 2018 Feb 11.

PMID:
29482102
40.

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.

Ricordel C, Friboulet L, Facchinetti F, Soria JC.

Ann Oncol. 2018 Jan 1;29(suppl_1):i28-i37. doi: 10.1093/annonc/mdx705.

PMID:
29462256
41.

Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130].

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2018 Apr;93:156-157. doi: 10.1016/j.ejca.2018.01.077. Epub 2018 Feb 14. No abstract available.

PMID:
29454743
42.

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.

Touat M, Sourisseau T, Dorvault N, Chabanon RM, Garrido M, Morel D, Krastev DB, Bigot L, Adam J, Frankum JR, Durand S, Pontoizeau C, Souquère S, Kuo MS, Sauvaigo S, Mardakheh F, Sarasin A, Olaussen KA, Friboulet L, Bouillaud F, Pierron G, Ashworth A, Lombès A, Lord CJ, Soria JC, Postel-Vinay S.

J Clin Invest. 2018 Apr 2;128(4):1671-1687. doi: 10.1172/JCI90277. Epub 2018 Mar 19.

43.

Epigenetic modifiers as new immunomodulatory therapies in solid tumours.

Aspeslagh S, Morel D, Soria JC, Postel-Vinay S.

Ann Oncol. 2018 Apr 1;29(4):812-824. doi: 10.1093/annonc/mdy050.

PMID:
29432557
44.

Multilayer global longitudinal strain in patients with cancer: A comparison of two vendors.

Ancedy Y, Ederhy S, Lang S, Hollebecque A, Dufour LS, Adavane-Scheuble S, Etienney A, Chauvet M, Soria JC, Cohen A.

Arch Cardiovasc Dis. 2018 Apr;111(4):285-296. doi: 10.1016/j.acvd.2017.11.003.

PMID:
29422386
45.

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.

Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, Soria JC, Ross JS, Miller VA, Stephens PJ, Lipson D, Yelensky R.

PLoS Comput Biol. 2018 Feb 7;14(2):e1005965. doi: 10.1371/journal.pcbi.1005965. eCollection 2018 Feb.

46.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684
47.

Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE.

Gaspar N, Marshall LV, Binner D, Herold R, Rousseau R, Blanc P, Capdeville R, Carleer J, Copland C, Kerloeguen Y, Norga K, Pacaud L, Sevaux MA, Spadoni C, Sterba J, Ligas F, Taube T, Uttenreuther-Fischer M, Chioato S, O'Connell MA, Geoerger B, Blay JY, Soria JC, Kaye S, Wulff B, Brugières L, Vassal G, Pearson ADJ; Members of Working Group 1 of the Paediatric Platform of ACCELERATE.

Ann Oncol. 2018 Mar 1;29(3):766-771. doi: 10.1093/annonc/mdy002. No abstract available.

48.

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.

Leduc C, Adam J, Louvet E, Sourisseau T, Dorvault N, Bernard M, Maingot E, Faivre L, Cassin-Kuo MS, Boissier E, Dessoliers MC, Robin A, Casiraghi O, Even C, Temam S, Olaussen KA, Soria JC, Postel-Vinay S.

ESMO Open. 2018 Jan 9;3(1):e000257. doi: 10.1136/esmoopen-2017-000257. eCollection 2018.

49.

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, Beyer U, Rhee I, Fine G, Winslow N, Chen DS, Wolchok JD.

J Clin Oncol. 2018 Mar 20;36(9):850-858. doi: 10.1200/JCO.2017.75.1644. Epub 2018 Jan 17.

PMID:
29341833
50.

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Bahleda R, Varga A, Bergé Y, Soria JC, Schnell D, Tschoepe I, Uttenreuther-Fischer M, Delord JP.

Br J Cancer. 2018 Feb 6;118(3):344-352. doi: 10.1038/bjc.2017.436. Epub 2018 Jan 16.

PMID:
29337963

Supplemental Content

Support Center